155 related articles for article (PubMed ID: 30827726)
1. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Brooks RA; Tritchler DS; Darcy KM; Lankes HA; Salani R; Sperduto P; Guntupalli S; DiSilvestro P; Kesterson J; Olawaiye AB; Moxley K; Waggoner S; Santin A; Rader JS; Kizer NT; Thaker PH; Powell MA; Mutch DG; Birrer MJ; Goodfellow PJ
Gynecol Oncol; 2019 May; 153(2):335-342. PubMed ID: 30827726
[TBL] [Abstract][Full Text] [Related]
2. Significant association of genetic polymorphism of human nonmetastatic clone 23 type 1 gene with an increased risk of endometrial cancer.
Wang PH; Yi YC; Tsai HT; Tee YT; Ko JL; Han CP; Liu YF; Lin LY; Yang SF
Gynecol Oncol; 2010 Oct; 119(1):70-5. PubMed ID: 20599259
[TBL] [Abstract][Full Text] [Related]
3. Associations of non-metastatic cells 1 gene polymorphisms with lymph node metastasis risk of gastric cancer in Northern Chinese population.
Li AL; Zhou X; Wang ZN; Song YX; Gao P; Miao Y; Zhu JL; Xu HM
Tumour Biol; 2012 Dec; 33(6):2159-66. PubMed ID: 22903495
[TBL] [Abstract][Full Text] [Related]
4. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
[TBL] [Abstract][Full Text] [Related]
5. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
[TBL] [Abstract][Full Text] [Related]
6. Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Topfedaisi Ozkan N; Öz M; Kimyon Comert G; Firat Cuylan Z; Çoban G; Turkmen O; Erdem B; Şahin H; Akbayır Ö; Dede M; Turan AT; Celik H; Güngör T; Haberal A; Arvas M; Meydanli MM
J Gynecol Oncol; 2018 Jul; 29(4):e48. PubMed ID: 29770619
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival.
Qu S; Long J; Cai Q; Shu XO; Cai H; Gao YT; Zheng W
Clin Cancer Res; 2008 Aug; 14(15):4787-93. PubMed ID: 18676749
[TBL] [Abstract][Full Text] [Related]
10. CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk.
O'Mara TA; Ferguson K; Fahey P; Marquart L; Yang HP; Lissowska J; Chanock S; Garcia-Closas M; Thompson DJ; Healey CS; Dunning AM; Easton DF; ; Webb PM; Spurdle AB
Twin Res Hum Genet; 2011 Aug; 14(4):328-32. PubMed ID: 21787115
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer risk.
Forma E; Wójcik-Krowiranda K; Jóźwiak P; Szymczyk A; Bieńkiewicz A; Bryś M; Krześlak A
Pathol Oncol Res; 2014 Jul; 20(3):597-602. PubMed ID: 24346708
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Moore KN; Tritchler D; Kaufman KM; Lankes H; Quinn MCJ; ; Van Le L; Berchuck A; Backes FJ; Tewari KS; Lee RB; Kesterson JP; Wenham RM; Armstrong DK; Krivak TC; Bookman MA; Birrer MJ
Gynecol Oncol; 2017 Nov; 147(2):396-401. PubMed ID: 28935272
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus.
Korkmaz V; Meydanli MM; Yalçın I; Sarı ME; Sahin H; Kocaman E; Haberal A; Dursun P; Güngör T; Ayhan A
J Gynecol Oncol; 2017 Nov; 28(6):e78. PubMed ID: 29027396
[TBL] [Abstract][Full Text] [Related]
14. Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification.
Zammarrelli WA; Kim SH; Da Cruz Paula A; Rios-Doria EV; Ehmann S; Yeoshoua E; Hanlon EJ; Zhou Q; Iasonos A; Alektiar KM; Aghajanian C; Makker V; Leitao MM; Abu-Rustum NR; Ellenson LH; Weigelt B; Mueller JJ
JCO Precis Oncol; 2022 Oct; 6():e2200194. PubMed ID: 36240474
[TBL] [Abstract][Full Text] [Related]
15. Nm23 expression in node-positive and node-negative endometrial cancer.
Yalçinkaya U; Ozuysal S; Bilgin T; Ercan I; Saraydaroglu O; Demir D
Int J Gynaecol Obstet; 2006 Oct; 95(1):35-9. PubMed ID: 16919631
[TBL] [Abstract][Full Text] [Related]
16. Association of polymorphisms in metastasis suppressor genes NME1 and KISS1 with breast cancer development and metastasis.
Antar S; Mokhtar N; Abd Elghaffar MA; Seleem AK
J Egypt Natl Canc Inst; 2020 May; 32(1):24. PubMed ID: 32462300
[TBL] [Abstract][Full Text] [Related]
17. Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
Turashvili G; Gómez-Hidalgo NR; Flynn J; Gonen M; Leitao MM; Soslow RA; Murali R
Gynecol Oncol; 2019 Jan; 152(1):38-45. PubMed ID: 30413340
[TBL] [Abstract][Full Text] [Related]
18. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
[TBL] [Abstract][Full Text] [Related]
19. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
Nugent EK; Bishop EA; Mathews CA; Moxley KM; Tenney M; Mannel RS; Walker JL; Moore KN; Landrum LM; McMeekin DS
Gynecol Oncol; 2012 Apr; 125(1):94-8. PubMed ID: 22155415
[TBL] [Abstract][Full Text] [Related]
20. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study.
Stålberg K; Bjurberg M; Borgfeldt C; Carlson J; Dahm-Kähler P; Flöter-Rådestad A; Hellman K; Hjerpe E; Holmberg E; Kjølhede P; Marcickiewicz J; Rosenberg P; Tholander B; Åvall-Lundqvist E; Högberg T
Acta Oncol; 2019 Nov; 58(11):1628-1633. PubMed ID: 31373248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
